Manning & Napier Group's EW Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 180 shares of Edwards Lifesciences Corporation (EW) worth $16,999, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 4 quarters.
Based on 13F filings, Manning & Napier Group has maintained this position in EW for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2026, adding 113 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +113 | Add 168.66% | 180 | $94.44 |
| Q2 2026 | +15 | Add 28.85% | 67 | $91.18 |
| Q1 2026 | +29 | Add 126.09% | 52 | $79.50 |
| Q4 2025 | +23 | New Buy | 23 | $86.22 |
Manning & Napier Group's Edwards Lifesciences Corporation Investment FAQs
Manning & Napier Group first purchased Edwards Lifesciences Corporation (EW) in Q4 2025, acquiring 23 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Edwards Lifesciences Corporation (EW) for 4 quarters since Q4 2025.
Manning & Napier Group's largest addition to Edwards Lifesciences Corporation (EW) was in Q3 2026, adding 180 shares worth $16,999.
According to the latest 13F filing for Q3 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 180 shares of Edwards Lifesciences Corporation (EW), valued at approximately $16,999.
As of the Q3 2026 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Edwards Lifesciences Corporation (EW) was 180 shares, as reported at the end of Q3 2026.